The Invisible Economy

Twenty

Twenty is not building another cybersecurity dashboard. It is building software for the sharp end of modern cyber conflict, where the customer is the U.S. military and intelligence community, the stakes are national security, and the product has to do more than look good in a demo.

Twenty has secured an additional $30M investment from Khosla Ventures at an approximately $1.2B valuation. The investment follows a $100M Series B led by Accel roughly one month earlier and brings the company's total funding to about $168M. CEO Joseph (Joe) Lin, Leo Olson, Skyler Onken, Peter (Pete) Sorrentino, and the broader team continue building one of the more closely watched companies in defense technology.

That is a remarkable funding trajectory, but the story extends well beyond the capital. Twenty is building AI-powered offensive cyber capabilities designed to automate parts of the cyber operations lifecycle for government operators. Reconnaissance, exploitation, multi-stage operations, and operator tradecraft are not exactly weekend hackathon territory. This is the kind of work where expertise, trust, and mission reliability matter long before anyone starts talking about scale.

Khosla Ventures' investment says something about where venture conviction is moving. Accel, Caffeinated Capital, General Catalyst, Friends & Family Capital, Point72 Ventures, and In-Q-Tel are already part of the investor base. That is not casual interest. It is another signal that defense technology has moved from a niche conversation to a serious software category.

There is a founder lesson here as well. The best markets are not always the loudest. Sometimes they are the ones most founders avoid because the domain is exceptionally difficult, the buyer is highly specialized, and the margin for error is almost nonexistent. Joseph Lin and the team brought military cyber and commercial security experience into a moment when AI is forcing governments to rethink how cyber operations are developed and executed.

That combination matters because national security software is not won by storytelling alone. It is won by teams that understand the mission, earn the trust of demanding customers, and translate difficult technical work into operational advantage without pretending the risks are small.

Twenty's name references the historic Twenty Committee, and the modern company is pursuing a similar principle: turning intelligence advantage into operational leverage. Different century. Different tools. The same reality that software has become part of national power.

This is why the investment matters. AI in cybersecurity is no longer just about faster alerts or cleaner dashboards. It is becoming part of the operating layer for defense, intelligence, and national security. Twenty is one of the companies making that shift impossible to ignore.

Natural

Natural just raised a $30M Series A to build payments infrastructure for AI agents. That sounds straightforward until you remember payments are anything but simple. They involve compliance, identity, settlement, permissions, fraud prevention, audit trails, disputes, banking relationships, and the financial plumbing that rarely gets noticed until something fails in public. That is exactly why this funding matters.

Natural is not building another checkout button. The San Francisco startup is developing the infrastructure that allows AI agents to hold funds, request payments, move money, and operate inside regulated financial systems without routing every transaction through a human with a keyboard.

The round was led by Kirsten Green at Forerunner, with continued backing from existing investors and operators across fintech and AI. Natural says the financing brings its total funding to more than $40M.

CEO Kahlil Lalji, CTO Eric Wang, CPO Walt Leung, and the broader Natural team are moving quickly, but what stands out is not just the capital. It is the clarity behind the company's strategy. Before the product had fully matured, Lalji reportedly wrote a 15-page memo outlining the future of agentic payments. That thesis helped Natural raise its seed round quickly and later announce a Series A when the company was only 193 days old. Founders should pay attention to that. Capital does not simply follow charisma. It follows a market thesis that makes the future specific enough for investors to underwrite.

The broader bet is straightforward: AI agents are moving from answering questions to completing work. Once software can book services, pay vendors, collect revenue, manage workflows, or coordinate operations, it needs more than intelligence. It needs financial permissioning, compliance, governance, and money movement designed for autonomous actors.

That represents a different category from traditional payment processing. The existing payments stack assumes a person authorizes every transaction. Agentic commerce assumes software can initiate, manage, and reconcile transactions on behalf of an individual or business. Natural is building around that assumption.

This is one of those infrastructure stories that could appear obvious in hindsight if the category develops as expected. The most visible AI companies may capture the headlines, but the infrastructure beneath them often captures enduring value once the market matures.

The question is no longer simply whether AI can complete the task. The more important question is whether an entire business process can operate safely, compliantly, and economically. Natural is betting the answer requires a new financial layer.

Cordant

Cordant coming out of stealth with an $8M seed round is not just another fintech infrastructure headline. It is a reminder that money can move at machine speed while accountability still crawls through disconnected systems looking for a clean answer.

That is the gap CEO Eric Rosenthal, CTO Lior Levitt, Chief Architect Sagi Ittah, and Chief Product Officer Juan Jose Huezo are pursuing. The former Rapyd leaders helped scale global payments infrastructure across more than 50 countries and 100 partner integrations. At that scale, the hard part is not always moving the transaction. The hard part is knowing what happened after the transaction touches banks, processors, ledgers, compliance tools, treasury systems, risk platforms, partner rails, and now stablecoin infrastructure.

Cordant is building what it calls a command center for financial infrastructure. Not another payment rail. Not another system asking institutions to replace the stack they already fought to install. Instead, the company connects existing systems into a shared operational view so banks, fintechs, payment companies, and digital asset firms can coordinate exceptions, audit activity, and understand money movement without centralizing funds or ripping out core workflows.

That distinction matters. AI in finance sounds powerful until it is pointed at fragmented operations with no shared context. Then it becomes a confident intern walking into a room where everyone is reading from a different ledger. Regulated institutions do not just need faster decisions. They need evidence, traceability, governance, and a timeline everyone can trust.

Motive Partners and Oak HC/FT co-led the round, joined by Bankless VC, FJ Labs, SignalFire, Quona, Next Stage, Selah Ventures, Flatironx, Nascent Ventures, Silvercircle Ventures, Generative Ventures, and design partner investors Bitso and Paxos. Cordant is also working with 11 design partners across banking, payments, embedded finance, cross-border payments, stablecoins, and digital assets, including Bitso, Paxos, OpenReserve, and Transcard.

The design partner list is the part operators should not overlook. The best infrastructure companies do not learn from clean architecture diagrams. They learn from the ugly edge cases where money moved, records disagree, compliance wants proof, treasury wants answers, and every system insists it is telling the truth.

That is the real signal. The market is not only funding faster financial rails. It is funding the context layer that makes those rails governable. The next generation of fintech infrastructure may not be defined by which platform moves money the fastest. It may be defined by which one makes every movement understandable, explainable, and accountable.

Augustus

Augustus just raised $180M in Series B funding at a $1B valuation, and the headline is not really about another fintech company becoming a unicorn. It is about the layer of finance that only seems boring until it breaks: dollar access, clearing, compliance, settlement, and the infrastructure behind global money movement.

The round was led by Tiger Global, with participation from QED Investors, Hummingbird Ventures, Brevan Howard Digital, Variant, Soma Capital, Road Capital Management, CMT Digital, Valar Ventures, and an experienced group of founder-investors. CEO Ferdinand Dabitz, Joshua Becker, Simon Wimmer, Peter Lieck, and the Augustus team are not building another application wrapped around someone else's rails. They are building the rails themselves.

Augustus calls its vision the Global Dollar Bank. The goal is to give international fintechs and banks programmable access to U.S. dollar accounts and payment infrastructure without forcing them through the traditional maze of intermediaries, disconnected systems, and banking relationships that become increasingly inefficient as businesses scale.

That vision became considerably more compelling after Augustus received conditional approval from the Office of the Comptroller of the Currency (OCC) for a U.S. national bank charter earlier this year. Conditional approval is not the finish line, but it is a meaningful regulatory milestone. In a market where many startups are still trying to appear inevitable, Augustus is doing the slower work that often makes infrastructure companies durable.

The company also operates regulated European banking infrastructure through Ivy Pay Oy, providing euro clearing and crypto on- and off-ramp capabilities. According to the company, that infrastructure supports billions in transaction volume through customers including Kraken. Marble, its AI-native banking platform, is designed to make U.S. dollar movement faster, more programmable, and less dependent on legacy middleware.

What makes this more than another funding announcement is the sequencing. Augustus tackled the difficult work first by building regulated European operations, pursuing a U.S. national bank charter, and developing an AI-native core designed for institutions that cannot afford shortcuts. It is not glamorous work. It is the kind of regulatory and technical foundation that is significantly harder to replicate than individual product features.

The lesson is straightforward. Investors did not commit $180M because Augustus had a compelling pitch deck. They backed a company combining regulatory progress, technical infrastructure, and a market problem that global fintechs already understand. Infrastructure rarely captures the attention economy in its early years. It compounds quietly, then becomes the foundation everyone later claims was obvious.

Neon Commerce

Neon Commerce just raised a $13M Series A to build a different kind of power layer for gaming: commerce infrastructure that lets publishers sell directly to players without pretending payments, tax, fraud, and compliance are side quests.

Andreessen Horowitz and Renegade Partners led the round, with Krafton participating as a strategic investor. The financing brings Neon's reported total funding to $27M. The number matters, but customer behavior matters more. CEO Chris Faught told GamesBeat that some studios using Neon now generate 50% to 70% of their gross revenue through direct-to-consumer channels.

Mobile game publishers have spent years renting distribution, customer access, and transaction economics from the platforms sitting between them and their players. Direct-to-consumer commerce changes that relationship. Publishers can own the storefront, control the customer experience, retain player data, and capture more of the economics while relying on a partner to handle the less glamorous work of tax, fraud, currency conversion, customer support, and payment routing.

That is Neon's lane. Its platform combines branded webshops, hosted and embedded checkout, global payments, and merchant-of-record services. Neon manages tax collection and remittance, compliance, currency conversion, disputes, and player support, allowing publishers to operate a true commerce channel instead of bolting a promotional storefront onto an existing game.

Legal and policy pressure surrounding app store payments has expanded opportunities for alternative purchase flows, even as the regulatory landscape continues to evolve. More importantly, direct commerce gives publishers something platform-controlled transactions rarely provide: a direct feedback loop showing who is buying, which offers convert, and how player behavior changes over time.

Krafton's participation makes this more than financial validation. Neon and Krafton began working together in 2025, and the publisher now uses Neon's payments and commerce infrastructure. A strategic investor with a live deployment can evaluate the platform against the operational complexity that rarely appears in investor presentations.

Neon plans to use the new capital to expand hiring, build loyalty capabilities, and enter additional markets. Direct commerce is moving from an optional margin optimization strategy to core infrastructure for game publishers. The companies that win will be the ones that remove complexity without taking ownership away from their customers.

The strongest signal is not that publishers want another checkout vendor. It is that they want a durable relationship with their players, and investors are increasingly backing the infrastructure that makes direct ownership possible.

Emergent Software

Emergent Software just made a grown-up move in a market full of grown-up problems. The Minneapolis Microsoft specialist secured a growth equity investment from Winterbird Partners to expand its team, build new capabilities, enter new geographies, and pursue strategic acquisitions. Financial terms were not disclosed. The more important signal is what both sides believe is worth scaling.

Founded in 2015 by Jamie Anderson and Mark Bajema, Emergent now lists Jamie Anderson as CEO, Mark Bajema as CIO, and Chris Lefstad as COO. The company built its business around a choice that sounded narrow before it became valuable: go deep on Microsoft instead of pretending every cloud platform, data stack, and AI tool deserves equal attention.

Microsoft Fabric, Azure, Copilot, Microsoft Foundry, and enterprise AI are landing inside organizations with legacy applications, fragmented data, cautious security teams, and governance meetings long enough to qualify as endurance sports. Buying technology is easy. Getting it all to operate like a single system is where budgets and patience disappear.

Emergent sits squarely in that execution gap. Its work spans data modernization, AI deployment, Azure cloud transformation, application development, security, governance, and managed services. The company holds six Microsoft Solutions Partner designations, multiple advanced specializations, Microsoft Fabric Featured Partner status, and Direct CSP status. This is not a consultancy that discovered Microsoft because AI became a boardroom priority last Tuesday.

Winterbird sees the same opportunity from the investment side. The Boston firm backs founder-owned B2B technology and services businesses with a strategy centered on talent expansion, service growth, geographic expansion, and strategic acquisitions. Eric Ahlgren, Founder and Managing Partner at Winterbird, said Emergent is on pace for its third consecutive year of revenue growth above 50%. That is an investor statement, but it reinforces the broader thesis: specialization is creating momentum, and Winterbird wants to accelerate it without diluting the founder-led culture that built the business.

The market lesson is not that services suddenly became fashionable. Enterprise AI has made implementation depth significantly more valuable. Models capture the headlines, but organizations still need clean data, secure cloud architecture, modern applications, governance, and teams that can connect every piece without turning implementation into a relay race between vendors. The next question is whether a focused Microsoft platform can scale its talent, geographic footprint, and acquisition strategy while preserving the technical credibility that created the opportunity in the first place.

Zafran Security

Zafran Security did not get acquired by Cisco. It gained something strategically interesting instead: Cisco Investments joined the cap table while Zafran continues building independently. On July 22, 2026, Zafran announced an undisclosed strategic investment from Cisco Investments, extending its previously announced $130M in total funding.

The size of the investment was not disclosed, and that is not the point. Cisco sells security infrastructure into many of the world's largest enterprises. Zafran is building the layer that helps those organizations make the tools they already own operate like a coordinated system instead of a crowded tool cabinet. Security teams do not lack alerts. They lack time, meaningful context, and a reliable way to determine which weakness is most likely to become an attack path before an attacker gets there first.

Zafran's AI-native Exposure Graph connects vulnerability findings with runtime presence, internet reachability, asset criticality, threat intelligence, and deployed controls. The platform identifies choke points and helps security teams mitigate or remediate the exposures most likely to lead to an incident.

The company says its annual recurring revenue more than tripled ahead of its December 2025 $60M Series C. It also says multiple Fortune 500 organizations across healthcare, technology, finance, and manufacturing use the platform to reduce remediation timelines from weeks to hours.

Co-Founder and CEO Sanaz Yashar brings incident response experience to the mission. Co-Founder and CTO Ben Seri translates that urgency into technical architecture, while Co-Founder Snir Havdala helped build the company around the same core insight: owning security tools is not enough if organizations cannot mobilize them quickly enough to matter.

Cisco Investments Vice President Janey Hoe described the opportunity in terms of orchestration rather than another dashboard. The focus is on a more unified security ecosystem that helps customers identify vulnerabilities and reduce infrastructure risk.

No Cisco or Splunk product integration was announced. The stronger signal is strategic alignment. Cisco sees value in an independent exposure management platform that can coordinate across increasingly complex enterprise security environments.

The business lesson for founders is straightforward. The strongest platform strategy is not always replacing everything a customer already owns. Sometimes the more valuable position is becoming the intelligence and action layer that helps existing technology finally deliver on its promise.

The investor fit tells the more compelling story. Enterprise security is shifting from finding more problems to coordinating faster action. If exposure management becomes the operating system for remediation instead of simply another place to count vulnerabilities, companies like Zafran could end up sitting at one of the most important control points in the modern security stack.

StrongestLayer

StrongestLayer just added $4.1M to its seed round. The more interesting question is what had to be true before Inovia Capital decided to lead it: a young cybersecurity company had to demonstrate that reasoning about an email can outperform simply recognizing one.

The seed extension brings StrongestLayer's total seed funding to $9.3M. LaunchPod, Alumni Ventures, Christopher Key, and returning investor Sorenson Capital also participated. The new capital will support go-to-market expansion and continued platform development.

Generative AI has made phishing cheaper, faster, and significantly more convincing. A well-crafted email can arrive from a familiar account, pass authentication, contain no malicious attachment, and still be engineered to steal money or credentials. Traditional filters are excellent at recognizing known patterns. Today's attackers create new ones with every campaign.

StrongestLayer built TRACE for exactly that challenge. Instead of waiting for a signature or obvious anomaly, the platform evaluates intent, potential harm, anomalies, and deception. It asks what a message is trying to accomplish and whether its details match the relationship it claims to represent. That reasoning powers email detection, Inbox Advisor, Threat Triage, and Threat Hunt across Microsoft 365 and Google Workspace.

The company's initial $5.2M seed round, led by Sorenson Capital in July 2025, funded the early product and customer validation. StrongestLayer told SiliconANGLE that production deployments have grown more than eightfold since that financing. That is a company-reported metric, but it helps explain why a new lead investor stepped in. Capital tends to follow evidence that a technical thesis can survive contact with real customers.

The founding team has spent years inside this category. CEO and Co-Founder Alan LeFort brings leadership experience from Proofpoint, McAfee, and Intel Security. CTO and Co-Founder Muhammad Rizwan has deep expertise in detection systems, including FireEye. CPO and Co-Founder Joshua Bass has held security leadership roles across Google, Mandiant, FireEye, and Proofpoint. This is not a team learning email security from a market map.

The broader lesson is both uncomfortable and useful. When the threat model changes, refining yesterday's detection model can become expensive theater. StrongestLayer now has another $4.1M to prove that its reasoning-first approach can become a repeatable product and a scalable business. The question for enterprise buyers is how quickly recognizing yesterday's attacks stops being enough to defend against tomorrow's.

Passionfroot

Passionfroot just raised a $15M Series A led by Insight Partners, with Creandum, Supernode Global, and s16vc returning for the next chapter. The headline is the capital. The more interesting story is B2B marketing acknowledging that trusted people often influence buying decisions more effectively than another polished advertisement nobody remembers.

Passionfroot is building the operating system around that shift. Its AI agent, Zest, helps teams plan creator campaigns, identify creators who reach the right buyers, execute campaigns, measure performance, and manage payments. Underneath it sits the Creator Graph, a proprietary dataset built from thousands of campaigns, alongside the Passionfroot Wallet for global payouts and attribution.

Creator marketing has spent years trying to operate like a mature channel while relying on spreadsheets, screenshots, scattered contracts, and dozens of invoices arriving from multiple countries. Passionfroot is building the infrastructure to make the process measurable, repeatable, and scalable for serious B2B growth teams without stripping away the human trust that makes creator marketing work in the first place.

The company says revenue grew 13x over the past year while remaining profitable with a team of just 15 people. It now works with more than 150 B2B brands across more than 20 industries, including ElevenLabs, Figma, Replit, Framer, and Gamma, alongside thousands of creators. Those company-reported metrics help explain why Insight Partners saw something larger than another marketplace business.

The Interactive Advertising Bureau (IAB) projects U.S. creator advertising spend will reach $44B in 2026, yet creator discovery, campaign measurement, and operational execution remain persistent challenges. Capital is flowing into the category faster than the supporting infrastructure. Passionfroot wants to build that missing operational layer for B2B.

The new funding will expand Zest's role in campaign execution, deepen the Creator Graph, and accelerate U.S. go-to-market operations. Co-Founder and CEO Jen Phan is relocating to New York to lead that expansion, while Co-Founder and CTO Lorenzo De Nobili continues leading product and engineering from Berlin. São Paulo serves as the company's third hub for customer success and engineering.

AI is making products easier to build, which makes distribution increasingly difficult to fake. As features multiply and markets become saturated with similar content, trusted domain experts become more valuable, not less. The winning platform may not be the one that generates the most content. It may be the one that helps companies identify the right voices, manage those relationships efficiently, and demonstrate measurable business results.

A $15M Series A gives Passionfroot additional room to scale the infrastructure behind creator-led growth. The next question is whether B2B companies begin treating creators as a core operating channel before their competitors do.

N-Zyme Biomedical

N-Zyme Biomedical just closed a $4.6M Series A to advance a different reflux thesis into the stage of biotech where the questions become expensive: human clinical studies. The company is advancing a Phase 2 trial in laryngopharyngeal reflux (LPR) while preparing development in proton pump inhibitor-refractory gastroesophageal reflux disease (GERD).

Reflux treatment has spent decades focused on acid. N-Zyme is targeting another factor that often remains after acid suppression: pepsin, the digestive enzyme associated with tissue damage and persistent reflux symptoms. Its lead program repurposes fosamprenavir, an HIV medicine with an established regulatory history, as an investigational pepsin inhibitor. The FDA approval applies to HIV treatment, not reflux. That distinction is important.

The biology remains early, but it is supported by encouraging preclinical research. Peer-reviewed studies have found that fosamprenavir can bind to and inhibit pepsin while protecting against pepsin-mediated injury in laboratory and animal models. N-Zyme announced the initiation of its Phase 2 LPR study in June under the leadership of Co-Founder and CSO Nikki Johnston, PhD, at the Medical College of Wisconsin. The public clinical trial registry, last updated before that announcement, still listed the study as not yet recruiting. The next meaningful milestone will come from human clinical data rather than scientific theory.

The new funding gives N-Zyme the opportunity to generate that evidence. Proceeds will support the Phase 2 LPR program, planned development for PPI-refractory GERD, regulatory activities, manufacturing, business development, and general corporate operations. The company did not disclose its investors, identifying only a group of healthcare professionals, entrepreneurs, a venture capital firm, and strategic investors.

Co-Founder and CEO Franco Vigile brings the operational perspective. Co-Founder and CSO Nikki Johnston brings years of academic research focused on pepsin, reflux-related tissue injury, and novel therapeutic approaches. Their thesis is not that reflux needs better marketing. It is that a disease category with limited options may require an entirely different therapeutic target.

That is the real signal behind this $4.6M financing. Early-stage biotech rounds are rarely defined by their size. They are defined by what the capital is intended to de-risk. N-Zyme now has the opportunity to demonstrate whether pepsin inhibition can move from a compelling biological mechanism supported by preclinical evidence to measurable clinical benefit for patients who have not responded to existing therapies.

The next chapter belongs to the data. If the company's hypothesis proves correct, the opportunity extends beyond another reflux therapy. It suggests the market may have been targeting only part of the disease while another biological driver remained largely untreated.

Inner Logic

Inner Logic just raised $11.5M to solve a problem medical device teams know too well: the physical world is expensive, slow, and impossible to simulate exhaustively with traditional development methods alone. The Baltimore company, previously known as Semaphor Surgical, builds simulation infrastructure for procedural medical devices. General Catalyst and Bison Ventures co-led the seed round, with J2 Ventures, Defined, PTX Ventures, Valia Ventures, Page One Ventures, Alumni Ventures, and Flare Capital Partners also participating.

Before a catheter, heart valve, or robotic surgical system reaches a patient, developers need to understand how it performs across different anatomies, imaging conditions, device interactions, and procedural complications. Prototypes, cadaver labs, and animal studies remain essential, but they cannot reproduce every rare scenario on demand.

Inner Logic wants to make those missing scenarios programmable. Its platform uses virtual patients and simulated procedures to evaluate device mechanics, generate synthetic data, and build in silico evidence before manufacturers commit additional time and capital to hardware-intensive testing and clinical studies. NVIDIA says Inner Logic is using its Medical Physics Simulation framework to support synthetic data generation, mechanics validation, and evidence development aligned with regulatory pathways.

That matters because the next generation of medical devices will not be defined by better hardware alone. Intelligent systems need an environment where they can fail safely before they succeed reliably. A platform capable of perceiving, planning, or acting during a procedure must contend with anatomical variation, noisy imaging, changing procedural conditions, and failure modes that rarely appear on a convenient laboratory schedule.

The founding team reflects that intersection of medicine, robotics, and computer science. Co-Founder and CEO Tito Porras, MD, MBA, leads the company alongside Co-Founder and CTO Mathias Unberath, PhD, a Johns Hopkins computer science professor, and Co-Founder and Chief Robotics Officer Axel Krieger, PhD, who directs the university's IMERSE Lab.

Their Johns Hopkins research lineage includes the STAR autonomous soft-tissue surgery program and later research demonstrating a robotic system completing a lengthy gallbladder-removal phase on lifelike porcine tissue. Those were important research milestones, not regulatory clearances for autonomous surgery, which is precisely why validation infrastructure matters.

The new funding gives Inner Logic the opportunity to expand its platform and support manufacturers building conventional, intelligent, and increasingly autonomous medical systems. The broader business lesson is straightforward: when a market's ambitions outpace its ability to test safely and efficiently, the testing infrastructure becomes one of the most valuable products in the ecosystem.

General Catalyst and Bison Ventures are betting that procedural intelligence needs a rigorous virtual proving ground before it earns trust in the operating room. If AI becomes a standard component of future medical devices, companies that help validate that intelligence may prove just as important as the companies building it.

Crystalys Therapeutics

Crystalys Therapeutics closed an oversubscribed $130M Series B. The more interesting story is what the round is designed to buy: clinical execution, commercial preparation, and a chance to turn a gout therapy already used across Asia into a second-line treatment option for patients in the United States and Europe.

Frazier Life Sciences led the financing, joined by Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, and KCap Biotechnology Fund. Every existing investor named in the announcement also participated, including Novo Holdings, SR One, Catalys Pacific, Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, abrdn-managed funds, KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners, and Prebys Ventures Fund.

The company's lead asset, dotinurad, is a once-daily oral URAT1 inhibitor designed to help the kidneys eliminate uric acid. Crystalys says more than 2.2 million patients have received the therapy since its 2020 launch in Japan. The drug is approved in Japan, China, the Philippines, Taiwan, and Thailand, but it remains investigational in North America and Europe.

The new capital will fund the Phase 3 RUBY and TOPAZ trials, the Phase 2 AMETHYST study, commercial preparation, and operations through anticipated clinical milestones. RUBY is expected to enroll approximately 500 adults with hyperuricemia associated with gout, TOPAZ about 250 adults with tophaceous gout, and AMETHYST roughly 90 patients who cannot tolerate xanthine oxidase inhibitors or have not responded to uricase therapy.

Crystalys raised a $205M Series A less than 10 months ago, bringing disclosed financing across the two rounds to $335M. The company is pursuing one of gout treatment's persistent gaps: what comes after first-line allopurinol is no longer sufficient but before patients reach the most refractory stages of disease. Biotech capital is not a trophy. It is an obligation to reduce uncertainty.

President and CEO James Mackay brings more than four decades of drug development and commercialization experience. Co-Founders Nihar Bhakta, Chief Medical Officer; Ashwin Ram, Chief Operating Officer; and DeAnne Reid, Executive Director of Operations and Business Development, contribute deep expertise in gout therapeutics and company building. Chief Financial Officer Justin Thacker adds the operational and financial discipline required to execute late-stage clinical development.

Kevin Li, Partner at Frazier Life Sciences, described the investment as a combination of a late-stage clinical asset, an experienced leadership team, and a significant unmet medical need. The next chapter is no longer about raising capital. It is about converting that capital into patient enrollment, meaningful clinical data, regulatory progress, and commercial readiness. If those pieces come together, gout treatment may finally gain a credible middle option between first-line therapy and the most difficult refractory cases.

Candid Health

Candid Health just raised $120M in Series D funding, and the number is only the admission price to the real story: healthcare billing has become infrastructure warfare. Sixth Street Growth led the round, with Oak HC/FT, 8VC, and Y Combinator returning. The financing triples Candid Health's valuation from its February 2025 Series C, although the company did not disclose its new valuation. Total disclosed funding now exceeds $219M.

Candid Health is rebuilding revenue cycle management from the data layer up. Its platform unifies clinical, billing, and provider data into a single model, applies configurable payer rules, and uses AI agents to automate work that billing teams have historically handled manually. Eligibility verification, claim submission, payment posting, and denial management are not administrative details. They are the operational machinery that determines whether healthcare providers get paid.

The company's traction makes that thesis increasingly difficult to dismiss. Candid Health reported 190% year-over-year growth in annual contracted run-rate revenue and 180% net dollar retention during 2025. It now serves more than 200 healthcare organizations across dozens of specialties. Customer examples, including Talkiatry and Nourish, point to reduced manual work alongside high collection rates and high levels of automated claims processing. Those are company- and customer-reported results, not universal guarantees. They still help explain why investors are paying attention. AI becomes genuinely valuable when it stops decorating an existing workflow and starts owning the difficult operational work inside it. That is not software garnish. It is operational leverage.

Nick Perry and Doug Proctor met at Palantir, where Perry focused on healthcare while Proctor built systems for defense and intelligence customers. Together with Adam Reis, they founded Candid Health in 2019. Perry serves as CEO, Proctor as COO, and Reis as Co-Founder. The deeper insight is that medical billing is fundamentally a data integration problem operating under more than a thousand payer rulebooks.

The United States spends an estimated $280B each year on healthcare revenue cycle management. Candid Health's bet is that the long-term winner will not bolt an AI assistant onto yesterday's software. It will become the financial system of record that healthcare organizations rely on every day.

Sixth Street Growth reportedly spoke with nearly 40 customers before making its investment. That is the kind of diligence typically associated with later-stage capital. Investors are underwriting more than AI enthusiasm. They are backing expansion, customer retention, and a platform that sits directly in the path of healthcare cash flow.

The larger question is whether autonomous revenue cycle management can reduce administrative complexity instead of simply replacing it with a newer layer of software. If Candid Health continues converting fewer manual touches into stronger collections, the answer may already be moving through the claims queue.

PRO-MAX

PRO-MAX has spent more than three decades doing the kind of work that only becomes visible when somebody did it badly the first time. Concrete restoration, waterproofing, painting, roofing, and interior renovation are not glamorous categories. They are the work that keeps buildings standing, property owners sane, and repair budgets from becoming cautionary tales.

Madison River Capital has made a strategic investment in the Miami-based contractor to support geographic expansion, broader service offerings, and team development. Financial terms were not disclosed, which matters because private-market arithmetic quickly becomes fiction when people fill in the blanks with confidence.

What is known is more meaningful than a valuation headline. Pro-Max serves condominium associations and commercial property owners across Florida, where aging buildings are colliding with stricter safety requirements. State law requires milestone structural inspections for qualifying condominium and cooperative buildings at 30 years, followed by inspections every 10 years. Local jurisdictions may require the first inspection at 25 years when conditions warrant it.

That creates durable demand for contractors that can do more than simply bid on a project. Pro-Max says most of its work is performed by its own employees, giving the company greater control over quality, scheduling, and costs. Its portfolio spans high-rise condominiums, hotels, retail properties, and commercial buildings, while its capabilities include structural strengthening, concrete repair, waterproofing, protective coatings, roofing, and full interior renovations.

Maximilian Tower founded Pro-Max in 1994 after learning the business through his family's South Florida painting company. Ray "Reggie" Rodriguez joined as a partner in 2006 after building experience in accounting, construction, and general contracting. Today, the two Co-Presidents lead a company that has expanded from commercial painting into a diversified building restoration platform.

Madison River Capital brings more than capital. Its operating approach focuses on expanding service lines and geographic reach, strengthening internal systems, and helping management teams scale. For Pro-Max, the opportunity is to grow beyond Florida without losing the owner involvement and field discipline that built its reputation. For Madison River Capital, the investment reflects a belief that aging infrastructure and stricter building safety requirements will continue supporting long-term demand for restoration services.

The more interesting question is how far a Florida specialist can scale a model built on self-performed work, broad technical capabilities, and more than three decades of earned trust. If restoration becomes an increasingly critical part of infrastructure spending, companies that consistently execute the difficult work may become far more valuable than those that simply win the next contract.